Goldman Sachs
EDIT icon

Goldman Sachs’s Editas Medicine EDIT Stock Holding History

Goldman Sachs’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-40,000
Closed -$960K – 6408
2017
Q3 		$960K Buy
40,000
+4,000
+11% +$76.1K ﹤0.01% 4605
2017
Q2 		$604K Buy
+36,000
New +$649K ﹤0.01% 4934

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Goldman Sachs's EDIT Position: Q2 2026 in Review

Goldman Sachs increased its Editas Medicine (EDIT) stake by 368% in Q2 2026, buying an estimated $6.01M and bringing the position to 2,614,036 shares worth $8.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3399.

Goldman Sachs first reported a position in EDIT in Q1 2016 and has held it in 42 quarters since. The position peaked at $71.8M in Q4 2020. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Goldman Sachs held 2,614,036 shares of Editas Medicine worth $8.47M as of Q2 2026.
  • Goldman Sachs bought 2,055,459 Editas Medicine shares in Q2 2026, an estimated $6.01M.
  • Editas Medicine made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3399 holding.
  • Goldman Sachs first reported a position in Editas Medicine in Q1 2016 and has held it in 42 quarters since.
  • Goldman Sachs's Editas Medicine position peaked at $71.8M in Q4 2020.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.